Riskpilot← Back to searchSign inGet full accessPERIOVACX AS
ASActiveOrg 916713894Bryggegata 6, 0250 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20160 employees
Revenue 2024
NOK 0
EBITDA margin
—
-505% vs 2023
Equity ratio
-13912.6%
Financial strength
Net profit 2024
NOK -13K
-506% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -13K | -505% |
| Net profit | NOK -13K | -506% |
| Total assets | NOK 1K | +0% |
| Equity | NOK -200K | -7% |
| Employees | 0 | — |
Legal name
PERIOVACX AS
Org number
916713894
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
17. februar 2016
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Forskning og utvikling innenfor tannhelse samt tilhørende investeringer og annet som naturlig faller sammen med dette.
Address
Bryggegata 6, 0250 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −13 | −36 | −30 | −28 | −45 | −36 | −21 | −2 | −13 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −13 | −36 | −30 | −28 | −45 | −36 | −21 | −2 | −13 |
| Net financials | 0 | −0 | 0 | −0 | −0 | 0 | 0 | 0 | 0 |
| Profit before tax | −13 | −36 | −30 | −28 | −45 | −36 | −21 | −2 | −13 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −13 | −36 | −30 | −28 | −45 | −36 | −21 | −2 | −13 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 18 | 3 | 7 | 8 | 1 | 3 | 3 | 1 | 1 |
| Equity | 11 | −25 | −54 | −83 | −128 | −164 | −185 | −187 | −200 |
| Long-term debt | 0 | 20 | 55 | 84 | 95 | 105 | 138 | 140 | 140 |
| Short-term debt | 6 | 7 | 6 | 7 | 34 | 62 | 49 | 48 | 62 |
| Total debt | 6 | 27 | 61 | 91 | 129 | 167 | 187 | 188 | 202 |
EBITDA margin
-1349800.0%
This company
15.8%
Market median
-8543138% vs market
20162024
Equity ratio
-13912.6%
This company
38.2%
Market median
-36520% vs market
20162024
Return on equity
-1349400.0%
This company
18.4%
Market median
-7333796% vs market
20162024
Net profit margin
-1349400.0%
This company
8.1%
Market median
-16659359% vs market
20162024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162024
Debt / equity
1.01×
This company
0.62×
Market median
-63% vs market
20162024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2016 | — | — | |
| Chairman | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Immunor As | Company | 68.8% | 68.8% | 2024 |
Kag As | Company | 12.5% | 12.5% | 2024 |
| Individual | 3.8% | 3.8% | 2024 | |
A A Holding As | Company | 3.8% | 3.8% | 2024 |
Wivel Invest As | Company | 3.8% | 3.8% | 2024 |
Dawa Consulting Aps | Company | 3.8% | 3.8% | 2024 |
Evnia Lvs | Company | 3.8% | 3.8% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Immunor As
PERIOVACX AS Board members of PERIOVACX AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Dag Arne Wivelstad | Board of Directors | 0 companies |
| Aslak Aslaksen | Board of Directors | 0 companies |
| Birger Sørensen | Chairman | 0 companies |